Looming fear of more IV shortages as Hurricane Rafael gains strength

Hurricane Rafael is currently gaining strength at sea, with the storm likely to enter the Gulf of Mexico later this week. While its path remains unclear, it could hit areas along the Gulf line, including Louisiana, Mississippi, Alabama and Texas.

As damage from September’s Hurricane Helene continues to cause IV solution shortages nationwide—in part because of damage to a Baxter manufacturing facility in North Carolina—nonprofit Healthcare Ready is sounding the alarm about the potential for further disruptions. 

Healthcare Ready is a charity that works with the government and private sector to address supply chain snags that could impact public health. In a Nov. 6 alert, the organization warned storm surge floods in Texas could damage the IV fluids supply chain, which is still recovering from Helene. 

The city of Austin produces roughly 4.4% of IV solutions in the U.S., and given that 86% of providers are reporting shortages, further disruptions to supplies could be devastating.

While the Baxter plant in North Carolina is recovering ahead of schedule, it is not expected to be operating at full capacity until December. That one location produces 60% of the IV solutions used by hospitals and healthcare providers in the U.S. 

For now, Healthcare Ready is monitoring the situation. It will update the alert on its website once more information on Rafael becomes available.

“Healthcare Ready works to monitor and evaluate the situation around the damage and provide analysis of its implications. We aim to provide information across sectors to supply information to all parties involved or impacted. Healthcare Ready is focusing efforts on highlighting challenges and supporting solutions to these challenges from the damages,” the group wrote.

More details on Healthcare Ready’s monitoring, along with links to resources for help with storm preparation and evacuation planning, can be found on its website’s alert hub

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.